Harmony Biosciences preannounces record Q2 2026 revenue, CFO steps down

Harmony Biosciences Holdings announced on July 16, 2026 preliminary, unaudited second-quarter 2026 net product revenue for WAKIX (pitolisant) of approximately $261 million, representing a new quarterly revenue record for the Company and growth of 30% year over year and 21% growth for Q2 over Q1.¹

The company said based on its first-half performance and current business trends, Harmony is reiterating its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion.¹ Full second-quarter results and a business update are scheduled for August 4, 2026, according to the release.

Separately, the company disclosed a leadership change. Chief Financial Officer Glenn Reicin has stepped down to pursue other opportunities, effective July 16, 2026.¹ Stephen Mollichella, the company's SVP and Controller, was appointed Interim Principal Financial Officer while Harmony searches for a permanent CFO.¹ Per the filing, since joining the company in 2021, Mollichella has led financial accounting and reporting functions, built the accounting team and key financial systems, and overseen financial governance and control processes while supporting business development activities.¹

Harmony stated that Reicin's departure does not stem from any disagreement with the company over its operations, policies, or practices, and that it does not expect the transition to affect performance or momentum.¹

Under a separation agreement filed as an exhibit, Reicin will receive severance payments and benefits under his employment agreement plus a pro-rated target bonus, in exchange for a release of claims and continued compliance with restrictive covenants.¹ The company noted Mollichella has no family relationships with any director or executive officer and no reportable related-party transactions under Item 404(a) of Regulation S-K.¹